89bio, Inc.
ETNB
$8.33
$0.151.83%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.74% | 32.08% | 38.20% | 45.48% | 35.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.40% | 124.48% | 55.43% | 70.31% | 47.88% |
| Operating Income | -154.40% | -124.48% | -55.43% | -70.31% | -47.88% |
| Income Before Tax | -164.88% | -124.95% | -43.75% | -52.99% | -35.60% |
| Income Tax Expenses | -82.10% | 26,787.50% | 22,666.67% | 21,922.22% | 20,252.63% |
| Earnings from Continuing Operations | -158.16% | -128.33% | -47.18% | -56.73% | -39.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.16% | -128.33% | -47.18% | -56.73% | -39.37% |
| EBIT | -154.40% | -124.48% | -55.43% | -70.31% | -47.88% |
| EBITDA | -154.45% | -124.53% | -55.46% | -70.36% | -47.92% |
| EPS Basic | -70.46% | -45.58% | 6.56% | 28.83% | 43.11% |
| Normalized Basic EPS | -72.87% | -43.15% | 7.92% | 29.53% | 43.38% |
| EPS Diluted | -70.46% | -45.58% | 6.56% | 28.83% | 43.11% |
| Normalized Diluted EPS | -72.87% | -43.15% | 7.92% | 29.53% | 43.38% |
| Average Basic Shares Outstanding | 47.26% | 50.70% | 56.51% | 90.58% | 104.92% |
| Average Diluted Shares Outstanding | 47.26% | 50.70% | 56.51% | 90.58% | 104.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
